Avenue Therapeutics, Inc. (ATXI)
OTC Markets OTCID
Price as at 30 Sept 2026, 16:12 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Avenue Therapeutics, Inc. trades at $0.40. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Avenue Therapeutics, Inc.
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include ATX-04, a small molecule therapy for the treatment of Pompe disease; and intravenous tramadol, a schedule IV opioid to treat post-operative acute pain. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Common questions
Where does SteadyShares get its ATXI data?
Fundamentals for ATXI come from company filings and exchange data, as listed on OTC Markets OTCID; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 16:12 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for ATXI, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.